Friday, February 23, 2018 10:51:04 AM
Sorry - longish answer. But you asked.
No chemical reaction is "100% reproducible" and 100% free from impurities.
Fluctuations in temperature, pressure, the times that each reaction step of a synthesis are allowed to proceed, and impurities within the different chemicals and reagents used in a reaction all contribute to variation. One tries to control these things as best as possible, of course.
When one speaks of "reproducibility", what specific aspects of a chemical synthesis are being referred to. Average particle size? Polymorph variants? Yield of the desired product? The amounts and types of impurities? etc etc.
When one synthesizes a nanoparticle polymer, for example, there will usually be a distribution of different nanoparticle sizes. It won't be the case that every particle in the end product has the exact same size. So the best one can do is give a statistical characterization of particles sizes, such as saying the sizes lie between X-nm and Y-nm in length, the average being Z-nm, show a plot of the distribution of sizes, etc. "Reproducibility" in this case would mean different batches of the material have the same statistical distribution of particle sizes.
Everything I've just mentioned will be different for every different type of molecule being synthesized.
To answer your questions after all of this: The FDA doesn't define required percentages. Everything measured will always be less-than 100%. It is a "negotiable percentage", in that you do what you can under GMP conditions, measure and quantify things, and make sure in your pre-IND meeting that your process will be good enough for the FDA to accept.
Typically, the FDA is most concerned about seeing a characterization of the impurities in the material being tested. They want to see that the percentage and types of those impurities are reliably reproduced between different batches of the material.
If your material, with its characterized impurity profile pass all the IND tox studies, the FDA will want to know that the material being tested in humans has at most those same percentages and types of impurities. In would be okay to make the material "better" than what was tested in IND tox, (fewer impurities or less % of the impurities), but it would be a problem if the material being tested in humans had *different* impurities than what was tested in IND tox.
I don't know what, if anything, additional the FDA requires for nanoparticle therapeutics beyond what is typically required. I'd imagine a characterization of particle size, and reproducibility of size-distribution.
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM